IBM Leverages $10 Billion in Credit and an Even Bigger Quantum Bet to Win Over Wall Street

JPMorgan has upgraded IBM to “Overweight” with a target price of roughly EUR 271, a move that comes as the company simultaneously locks down long-term financing and pours billions into quantum computing. The stock has responded accordingly, climbing about 7% over the past week to trade near EUR 233 at press time, after closing at EUR 231.40 earlier in the week. The analyst upgrade centers on IBM’s software portfolio, where platforms like OpenShift generate roughly $2 billion annually in high-margin, recurring revenue.

That software-driven optimism is backed by an unusually aggressive balance-sheet manoeuvre. IBM has extended two credit facilities totalling $10 billion through to 2029 and 2031, giving management maximum flexibility to fund its internal transformation. The capital cushion comes just as the company commits to spending more than $10 billion on quantum computing over the next five years—a separate investment earmarked for research, production, ecosystem partnerships and acquisitions.

Chief Executive Arvind Krishna used the first-quarter earnings call to pin a timeline on that quantum bet. “We are convinced that our partners will achieve their first examples of quantum supremacy this year—on IBM hardware,” he said. The target is to deliver the world’s first large-scale, fault-tolerant quantum computer by 2029. IBM already operates the largest fleet of quantum machines globally, works with more than 340 organisations running real workloads, and has consistently hit its published quantum roadmap year after year.

On the cybersecurity front, IBM is deepening its partnership with Red Hat and Palo Alto Networks. The three companies are integrating Palo Alto’s “virtual patching” technology into IBM’s existing systems, combining network-level protection with direct software fixes. The alliance aims to accelerate the detection and remediation of software vulnerabilities, particularly against AI-driven cyber threats.

Should investors sell immediately? Or is it worth buying IBM?

Technical indicators paint a mixed picture of the stock’s near-term momentum. Shares trade 7.07% above the 50-day moving average but remain 1.20% below the 200-day average of EUR 235.82, placing them in neutral territory. The Relative Strength Index stands at 53, signalling neither overbought euphoria nor oversold capitulation. The consensus analyst price target is EUR 256.21, implying roughly 10% upside, though JPMorgan’s EUR 271 target suggests even more room if the software story holds. One striking number is the 30-day annualised volatility of 68%—hardly typical of a mature blue chip, indicating the market is actively revaluing the company.

Underpinning the long-term thesis is IBM’s hybrid approach to quantum computing, which combines quantum processors with classical systems for data preparation and error correction. The company plans to introduce a real-time error-correction decoder in 2026, and the Nighthawk processor is on track to run circuits with 7,500 gates using up to three 120-qubit modules. A concrete example of progress: researchers at the Cleveland Clinic used IBM quantum hardware to simulate a molecular system with 300 atoms, a breakthrough for drug development. Krishna calls the hybrid model essential for moving quantum from isolated demonstrations into genuine industrial applications.

Looking ahead, IBM reports its next quarterly results on July 22, 2026. The market expects earnings per share of $2.95 on revenue of roughly $17.9 billion. Between the $10 billion credit buffer, the equally large quantum commitment, and a software business that continues to churn out dependable cash, the company is positioning itself as something more than a turn-of-the-century mainframe relic—though whether the quantum payoff arrives by 2029 remains the defining question.